
A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

In this Q&A, Levy discusses the current treatment landscape for PBC and what clinical trial data suggest about seladelpar’s potential for these patients.

Fendrick explains the value of additional modalities for colorectal cancer screening to combat the colonoscopy backlog and help patients get screened.

A retrospective analysis in the US found bariatric surgery lowers mortality rates and shortens hospital stays in patients admitted with NAFLD.

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Initial consultations by female gastroenterologists led to a significant reduction in subsequent healthcare utilization compared with male gastroenterologists.

Jared Hassler, MD, shares his personal journey with IgAN and discusses IgAN's clinical features and diagnosis, emphasizing the importance of routine screenings for early detection.

Patients with IgAN receiving iptacopan achieved a 38.3% reduction in proteinuria at month 9.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!

Findings demonstrated a slower decline in kidney function for patients treated with sparsentan or irbesartan compared with standard of care in both real-world and clinical trial settings.

Kam Kalantar-Zadeh, MD, MPH, PhD, discusses his presentation focusing on dietary challenges, potassium control, and potential solutions associated with RAASi therapy.

Kam Kalantar-Zadeh, MD, MPH, PhD, addresses the challenge healthcare providers encounter in balancing the cardiovascular advantages of RAASi therapy with the potential hazards of hyperkalemia.

From the prospect of semaglutide and MDMA for substance use disorder to evolving research around personality disorders and OCD, here are 5 key topics from the annual psychiatric meeting.

Maya N. Clark-Cutaia, PhD, ACNP-BC, RN, highlights strategies to improve cardiovascular disease-related outcomes in patients with ESKD.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for micronutrient supplementation!

Areef Ishani, MD, MS, discusses the results of the Diuretic Comparison Project (DCP), which compared chlorthalidone and hydrochlorothiazide for the treatment of cardiovascular diseases.

New analyses show adults aged ≥65 years old are at about 30% increased risk of hypertension when diagnosed with diabetes mellitus.

Sylvia Rosas, MD, MSCE, discusses highlights from the National Kidney Foundation's Spring Clinical Meeting, including innovations in xenotransplantation, artificial intelligence, and the interplay between kidney, heart, and metabolic diseases.

Swapnil Hiremath, MD, MPH, explains the importance of 24-hour ambulatory blood pressure monitoring (ABPM) to rule out the possibility of white coat hypertension.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for nutritional assessments!

A post hoc analysis from FIDELITY shows finerenone could significantly reduce eGFR slopes among patients at risk of worsening CKD due to a heart failure hospitalization.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

Oldham highlights the anticipated change to a more dimensional perspective on personality disorders in new guidelines anticipated later this year.

In an interview, King provided an overview of the history of psychedelic research for psychiatric conditions, where we are now, and what hurdles investigators must address.

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

Sibille and colleagues have made progress in refining the therapeutic pathways of Alzheimer disease. Human trials may soon follow.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.

At ARVO 2024, Nazlee Zebardast, MD, MSc describes the value of a polygenic risk score to predict the onset of primary open-angle glaucoma.